NO310703B1 - Fremgangsmåte for fremstilling av tablettformulering som omfatter amoxycillin og klavulanat - Google Patents
Fremgangsmåte for fremstilling av tablettformulering som omfatter amoxycillin og klavulanat Download PDFInfo
- Publication number
- NO310703B1 NO310703B1 NO19964488A NO964488A NO310703B1 NO 310703 B1 NO310703 B1 NO 310703B1 NO 19964488 A NO19964488 A NO 19964488A NO 964488 A NO964488 A NO 964488A NO 310703 B1 NO310703 B1 NO 310703B1
- Authority
- NO
- Norway
- Prior art keywords
- tablet
- weight
- amoxycillin
- clavulanate
- film coating
- Prior art date
Links
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 title claims description 40
- 229960003022 amoxicillin Drugs 0.000 title claims description 32
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 title claims description 32
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 title claims description 31
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 title claims description 30
- 229940090805 clavulanate Drugs 0.000 title claims description 25
- 239000007916 tablet composition Substances 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title description 5
- 239000007888 film coating Substances 0.000 claims description 31
- 238000009501 film coating Methods 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 27
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 18
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 18
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 6
- 238000007906 compression Methods 0.000 claims description 6
- 230000006835 compression Effects 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 4
- 239000008109 sodium starch glycolate Substances 0.000 claims description 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 11
- 229960003324 clavulanic acid Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000009490 roller compaction Methods 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- -1 alkali metal salts Chemical class 0.000 description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002132 β-lactam antibiotic Substances 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940038649 clavulanate potassium Drugs 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 208000027136 gram-positive bacterial infections Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9408117A GB9408117D0 (en) | 1994-04-23 | 1994-04-23 | Pharmaceutical formulations |
| PCT/EP1995/001463 WO1995028927A1 (en) | 1994-04-23 | 1995-04-19 | Polymer coated tablet comprising amoxycillin and clavulanate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO964488D0 NO964488D0 (no) | 1996-10-22 |
| NO964488L NO964488L (no) | 1996-12-17 |
| NO310703B1 true NO310703B1 (no) | 2001-08-20 |
Family
ID=10754044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19964488A NO310703B1 (no) | 1994-04-23 | 1996-10-22 | Fremgangsmåte for fremstilling av tablettformulering som omfatter amoxycillin og klavulanat |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6051255A (pt) |
| EP (5) | EP0978276B1 (pt) |
| JP (1) | JP3622975B2 (pt) |
| CN (1) | CN1134258C (pt) |
| AP (2) | AP564A (pt) |
| AT (6) | ATE203161T1 (pt) |
| AU (1) | AU684949B2 (pt) |
| BG (1) | BG62842B1 (pt) |
| BR (1) | BR9507502A (pt) |
| CA (1) | CA2188496A1 (pt) |
| CZ (2) | CZ294168B6 (pt) |
| DE (5) | DE29522153U1 (pt) |
| DK (4) | DK1093813T3 (pt) |
| DZ (1) | DZ1876A1 (pt) |
| ES (4) | ES2152485T3 (pt) |
| FI (1) | FI964249A (pt) |
| GB (1) | GB9408117D0 (pt) |
| GR (2) | GR3035031T3 (pt) |
| HK (5) | HK1027024A1 (pt) |
| HU (1) | HU228399B1 (pt) |
| IL (1) | IL113433A (pt) |
| MA (1) | MA23528A1 (pt) |
| MY (1) | MY115351A (pt) |
| NO (1) | NO310703B1 (pt) |
| NZ (1) | NZ285080A (pt) |
| OA (1) | OA10377A (pt) |
| PL (1) | PL316966A1 (pt) |
| PT (4) | PT1093813E (pt) |
| RO (1) | RO116997B1 (pt) |
| RU (1) | RU2152213C1 (pt) |
| SA (1) | SA95160343B1 (pt) |
| SI (1) | SI0758235T1 (pt) |
| SK (1) | SK282594B6 (pt) |
| WO (1) | WO1995028927A1 (pt) |
| ZA (1) | ZA953236B (pt) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
| GB9408117D0 (en) * | 1994-04-23 | 1994-06-15 | Smithkline Beecham Corp | Pharmaceutical formulations |
| DZ2028A1 (fr) * | 1995-05-03 | 2002-10-23 | Smithkline Beecham Plc | Médicaments destinés au traitement d'infections bactériennes en pédiatrie. |
| US20030109503A1 (en) * | 1995-06-06 | 2003-06-12 | Smithkline Beecham P.L.C. | Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics |
| KR100495585B1 (ko) * | 1995-09-07 | 2005-09-09 | 스미스클라인비이참피이엘시이 | 제약 제제 |
| AT407701B (de) * | 1996-08-12 | 2001-05-25 | Biochemie Gmbh | Zur direkttablettierung geeignete mischung, die als wesentliche komponenten amoxicillin-trihydrat und das kaliumsalz der clavulansäure enthält und verfahren zur herstellung dieser mischung |
| TWI225402B (en) * | 1996-03-13 | 2004-12-21 | Biochemie Gmbh | Auxiliary-free agglomerates |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| GB9616536D0 (en) * | 1996-08-06 | 1996-09-25 | Quadrant Holdings Cambridge | Co-amoxiclav dosage form |
| GB9617780D0 (en) * | 1996-08-24 | 1996-10-02 | Smithkline Beecham Plc | Method of treatment |
| AU6496498A (en) * | 1997-02-07 | 1998-08-26 | Gist-Brocades B.V. | Homogeneous granulated formulations for dose sipping technology |
| EP0975342B1 (en) * | 1997-02-14 | 2003-06-25 | Laboratoire GlaxoSmithKline S.A.S. | Pharmaceutical formulations comprising amoxocyllin and clavulanate |
| US20030124187A1 (en) * | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| CN1268888A (zh) * | 1997-08-29 | 2000-10-04 | Dsm公司 | 不含赋形剂的颗粒 |
| JP2001521910A (ja) | 1997-10-31 | 2001-11-13 | モンサント カンパニー | ゲランガム錠剤コーティング |
| ES2215628T5 (es) | 1999-04-01 | 2011-11-28 | Dsm Ip Assets B.V. | Aglomerados obtenidos por cristalización. |
| US7250176B1 (en) * | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
| US6294199B1 (en) * | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
| US6878386B1 (en) | 1999-04-13 | 2005-04-12 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
| PL197448B1 (pl) * | 1999-04-13 | 2008-03-31 | Beecham Pharm Pte Ltd | Preparat farmaceutyczny o zmodyfikowanym uwalnianiu zawierający amoksycylinę i klawulanian potasowy oraz zastosowanie amoksycyliny i klawulanianu potasowego |
| US20040038948A1 (en) * | 1999-12-07 | 2004-02-26 | Uhrich Kathryn E. | Therapeutic compositions and methods |
| GB9930578D0 (en) * | 1999-12-23 | 2000-02-16 | Smithkline Beecham Plc | Pharmaceutical formulations |
| US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| AU2001279284A1 (en) * | 2000-07-05 | 2002-01-14 | Capricorn Pharma, Inc | Rapid-melt semi-solid compositions, methods of making same and methods of using same |
| US6375982B1 (en) * | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
| WO2002030392A2 (en) | 2000-10-12 | 2002-04-18 | Beecham Pharmaceuticals (Pte) Limited | Formulation containing amoxicillin |
| US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
| US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
| US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| US20020197314A1 (en) * | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
| US20030070584A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
| AU4061702A (en) * | 2001-05-15 | 2003-04-03 | Mcneil-Ppc, Inc. | Dip coating compositions containing starch or dextrin |
| US8309118B2 (en) * | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
| WO2003066053A1 (en) * | 2002-02-07 | 2003-08-14 | Rutgers, The State University | Antibiotic polymers |
| GB0203528D0 (en) * | 2002-02-14 | 2002-04-03 | Glaxo Group Ltd | Process and composition |
| KR100967782B1 (ko) * | 2002-02-14 | 2010-07-05 | 글락소 그룹 리미티드 | Ｎ-((1-Ｎ-부틸-4-피페리디닐)메틸)-3,4-디하이드로-2Ｈ-(1,3)옥사지노(3,2-ａ)인돌-10-카복스아미드 또는 그의 염을포함하는 제약 조성물, 및 건식 과립화를 포함하는 그의제조 방법 |
| US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
| KR100456833B1 (ko) * | 2002-08-01 | 2004-11-10 | 주식회사 대웅 | 아목시실린 및 클라불라네이트를 함유하는 유핵정 |
| US7429619B2 (en) * | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
| CA2406592C (en) * | 2002-10-04 | 2003-09-30 | Duchesnay Inc. | Method of preparing pharmaceutical dosage forms containing multiple active ingredients |
| US7405210B2 (en) | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
| AU2004258953B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| AU2004258944B2 (en) * | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| AU2004258949B2 (en) * | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| AU2004264939A1 (en) * | 2003-08-11 | 2005-02-24 | Middlebrook Pharmaceuticals, Inc. | Robust pellet |
| CA2535398C (en) * | 2003-08-12 | 2013-11-12 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
| CA2535780A1 (en) * | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
| DE10341264A1 (de) | 2003-09-04 | 2005-03-24 | Grünenthal GmbH | Schmelzformulierte, multipartikuläre orale Darreichungsform |
| AU2004273830B2 (en) * | 2003-09-15 | 2011-03-24 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| JP2007517039A (ja) * | 2003-12-24 | 2007-06-28 | アドバンシス ファーマスーティカル コーポレイション | 変性放出製剤の吸収増強 |
| ES2353309T3 (es) | 2004-03-08 | 2011-03-01 | Prosidion Ltd. | Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa. |
| EP1771158A4 (en) * | 2004-07-02 | 2008-03-12 | Advancis Pharmaceutical Corp | TABLET FOR PULSED DELIVERY |
| KR100638315B1 (ko) * | 2004-07-23 | 2006-10-25 | 주식회사 대웅제약 | 다중 필름 코팅된 코어층을 갖는 클라불라네이트 및아목시실린-함유 유핵정 |
| WO2006123765A1 (ja) | 2005-05-20 | 2006-11-23 | Daiichi Sankyo Company, Limited | フィルムコーティング製剤 |
| KR100780553B1 (ko) * | 2005-08-18 | 2007-11-29 | 한올제약주식회사 | 메트포르민 서방정 및 그의 제조방법 |
| US8778924B2 (en) * | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
| US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
| US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| CL2008003230A1 (es) * | 2007-11-01 | 2009-11-27 | Sanofi Aventis Healthcare Pty Ltd | Composicion de recubrimiento de tableta que comprende polimero celulosico, plastificante, edulcorante y composicion de sabor en polvo la que comprende saborizante asociado con portador solido; fluido de recubrimiento de tableta que comprende dicha composicion; tableta farmaceutica; proceso de preparacion de dicha tableta. |
| UA115979C2 (uk) * | 2009-09-18 | 2018-01-25 | Санофі | Таблетований препарат (4'-трифторметилфеніл)аміду (z)-2-ціано-3-гідроксибут-2-еноєвої кислоти з поліпшеною стійкістю |
| TR200909787A2 (tr) | 2009-12-25 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar. |
| TR201000687A1 (tr) | 2010-01-29 | 2011-08-22 | Bi̇lgi̇ç Mahmut | Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar |
| TR201000686A1 (tr) | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@ |
| TR201000688A2 (tr) | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar. |
| JP6041591B2 (ja) * | 2011-09-13 | 2016-12-14 | 大日本住友製薬株式会社 | イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物 |
| US9387250B2 (en) | 2013-03-15 | 2016-07-12 | Rutgers, The State University Of New Jersey | Therapeutic compositions for bone repair |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1241844A (en) | 1968-08-23 | 1971-08-04 | Beecham Group Ltd | Penicillins |
| GB1508977A (en) | 1974-04-20 | 1978-04-26 | Beecham Group Ltd | Beta-lactam antibiotic from streptomyces clavuligerus |
| US4098897A (en) * | 1975-04-14 | 1978-07-04 | Beecham Group Limited | Anti bacterial agents |
| JO984B1 (en) | 1977-10-11 | 1979-12-01 | بيتشام غروب ليمتد | A dry pharmaceutical compound with a suitable dosage unit for oral administration |
| NZ198241A (en) * | 1980-09-27 | 1983-12-16 | Beecham Group Ltd | Tablet containing amoxycillin and potassium clavulanate |
| EP0080862B1 (en) * | 1981-12-02 | 1985-09-25 | Beecham Group Plc | Pharmaceutical formulation comprising beta-lactam antibiotics |
| GB9408117D0 (en) * | 1994-04-23 | 1994-06-15 | Smithkline Beecham Corp | Pharmaceutical formulations |
| PL197448B1 (pl) * | 1999-04-13 | 2008-03-31 | Beecham Pharm Pte Ltd | Preparat farmaceutyczny o zmodyfikowanym uwalnianiu zawierający amoksycylinę i klawulanian potasowy oraz zastosowanie amoksycyliny i klawulanianu potasowego |
| WO2002030392A2 (en) * | 2000-10-12 | 2002-04-18 | Beecham Pharmaceuticals (Pte) Limited | Formulation containing amoxicillin |
-
1994
- 1994-04-23 GB GB9408117A patent/GB9408117D0/en active Pending
-
1995
- 1995-04-13 AP APAP/P/1995/000733A patent/AP564A/en active
- 1995-04-19 AT AT95917937T patent/ATE203161T1/de active
- 1995-04-19 EP EP99200891A patent/EP0978276B1/en not_active Expired - Lifetime
- 1995-04-19 EP EP00204182A patent/EP1093813B1/en not_active Revoked
- 1995-04-19 RU RU96122474/14A patent/RU2152213C1/ru active
- 1995-04-19 DE DE29522153U patent/DE29522153U1/de not_active Expired - Lifetime
- 1995-04-19 CA CA002188496A patent/CA2188496A1/en not_active Abandoned
- 1995-04-19 PL PL95316966A patent/PL316966A1/xx unknown
- 1995-04-19 PT PT00204182T patent/PT1093813E/pt unknown
- 1995-04-19 PT PT95917937T patent/PT758235E/pt unknown
- 1995-04-19 ES ES96202848T patent/ES2152485T3/es not_active Expired - Lifetime
- 1995-04-19 EP EP96202848A patent/EP0761218B1/en not_active Revoked
- 1995-04-19 DE DE69521799T patent/DE69521799T2/de not_active Expired - Lifetime
- 1995-04-19 EP EP02076874A patent/EP1243267A3/en not_active Withdrawn
- 1995-04-19 ES ES00204182T patent/ES2182754T3/es not_active Expired - Lifetime
- 1995-04-19 WO PCT/EP1995/001463 patent/WO1995028927A1/en active IP Right Grant
- 1995-04-19 AU AU24068/95A patent/AU684949B2/en not_active Expired
- 1995-04-19 JP JP52733495A patent/JP3622975B2/ja not_active Expired - Lifetime
- 1995-04-19 DK DK00204182T patent/DK1093813T3/da active
- 1995-04-19 ES ES95917937T patent/ES2161288T3/es not_active Expired - Lifetime
- 1995-04-19 AT AT96202848T patent/ATE196845T1/de not_active IP Right Cessation
- 1995-04-19 PT PT96202848T patent/PT761218E/pt unknown
- 1995-04-19 HU HU9602922A patent/HU228399B1/hu unknown
- 1995-04-19 NZ NZ285080A patent/NZ285080A/en not_active IP Right Cessation
- 1995-04-19 DK DK96202848T patent/DK0761218T3/da active
- 1995-04-19 DK DK95917937T patent/DK0758235T3/da active
- 1995-04-19 EP EP95917937A patent/EP0758235B1/en not_active Expired - Lifetime
- 1995-04-19 PT PT99200891T patent/PT978276E/pt unknown
- 1995-04-19 CZ CZ19963090A patent/CZ294168B6/cs not_active IP Right Cessation
- 1995-04-19 DK DK99200891T patent/DK0978276T3/da active
- 1995-04-19 SK SK1354-96A patent/SK282594B6/sk not_active IP Right Cessation
- 1995-04-19 CN CNB951934023A patent/CN1134258C/zh not_active Expired - Lifetime
- 1995-04-19 AT AT99200891T patent/ATE223706T1/de active
- 1995-04-19 DE DE69528608T patent/DE69528608T2/de not_active Revoked
- 1995-04-19 BR BR9507502A patent/BR9507502A/pt not_active IP Right Cessation
- 1995-04-19 AP APAP/P/1996/000868A patent/AP9600868A0/en unknown
- 1995-04-19 US US08/727,581 patent/US6051255A/en not_active Expired - Lifetime
- 1995-04-19 DE DE69528204T patent/DE69528204T2/de not_active Expired - Lifetime
- 1995-04-19 CZ CZ200011418U patent/CZ11376U1/cs not_active IP Right Cessation
- 1995-04-19 SI SI9530526T patent/SI0758235T1/xx unknown
- 1995-04-19 AT AT00204182T patent/ATE226074T1/de not_active IP Right Cessation
- 1995-04-19 ES ES99200891T patent/ES2180251T3/es not_active Expired - Lifetime
- 1995-04-19 RO RO96-02030A patent/RO116997B1/ro unknown
- 1995-04-19 DE DE69519093T patent/DE69519093T2/de not_active Expired - Fee Related
- 1995-04-20 MY MYPI95001037A patent/MY115351A/en unknown
- 1995-04-20 IL IL11343395A patent/IL113433A/xx unknown
- 1995-04-21 MA MA23858A patent/MA23528A1/fr unknown
- 1995-04-21 ZA ZA953236A patent/ZA953236B/xx unknown
- 1995-04-22 DZ DZ950044A patent/DZ1876A1/fr active
- 1995-10-25 SA SA95160343A patent/SA95160343B1/ar unknown
-
1996
- 1996-10-22 FI FI964249A patent/FI964249A/fi not_active Application Discontinuation
- 1996-10-22 NO NO19964488A patent/NO310703B1/no not_active IP Right Cessation
- 1996-10-23 OA OA60908A patent/OA10377A/en unknown
- 1996-10-23 BG BG100933A patent/BG62842B1/bg unknown
-
1998
- 1998-09-21 HK HK00104976A patent/HK1027024A1/xx not_active IP Right Cessation
- 1998-09-21 HK HK01107178A patent/HK1036404A1/xx not_active IP Right Cessation
- 1998-09-21 HK HK99105804A patent/HK1021860A1/xx not_active IP Right Cessation
- 1998-09-21 HK HK98110787A patent/HK1009936A1/xx not_active IP Right Cessation
- 1998-09-21 HK HK03101681.9A patent/HK1050992A1/zh unknown
-
2000
- 2000-07-18 AT AT0052400U patent/AT5349U1/de not_active IP Right Cessation
- 2000-12-12 GR GR20000402718T patent/GR3035031T3/el not_active IP Right Cessation
-
2001
- 2001-04-11 AT AT0028501U patent/AT5350U1/de not_active IP Right Cessation
- 2001-10-09 GR GR20010401708T patent/GR3036844T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO310703B1 (no) | Fremgangsmåte for fremstilling av tablettformulering som omfatter amoxycillin og klavulanat | |
| EP3509581B1 (en) | Formulations of (r)-2-amino-3-phenylpropyl carbamate | |
| JP5934812B2 (ja) | 制御放出の製剤処方または食品処方およびその製造方法 | |
| NO327801B1 (no) | Formulering med retardert frigivning, anvendelse derav og fremgangsmate for fremstilling av formuleringen. | |
| EA002595B1 (ru) | Фармацевтический препарат, содержащий амоксициллин и клавуланат, способ его приготовления и гранулят, содержащий амоксициллин и клавуланат | |
| TW200815032A (en) | Use of polyols to obtain stable polymorphous forms of rifaximin | |
| RU2444359C1 (ru) | Фармацевтическая композиция с 2-этил-6-метил-3-гидроксипиридина сукцината для перорального применения и способ ее получения | |
| US20070087051A1 (en) | Pharmaceutical composition | |
| EA015519B1 (ru) | Фармацевтическая композиция, содержащая активный ингредиент аторвастатин | |
| NZ290806A (en) | Preparation of tablets of fusidic acid, sodium salt | |
| WO2002020018A1 (en) | Tablets containing epinastine manufactured by direct compression | |
| RU2622754C1 (ru) | Драже с изониазидом и офлоксацином для лечения туберкулеза | |
| RU2589502C1 (ru) | Лекарственное средство и способы его получения (варианты) | |
| MXPA96005055A (en) | Polymer revestible tablet that comprises amoxicillin and clavulan | |
| WO2016042567A1 (en) | Extended release formulation of metformin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |